Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Aminothiazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 known ✓ | P29475 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminothiazole SCHEMBL4466019 | 0.98 | ALDH1A1 (0.68) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL1003511 | 0.98 | ALDH1A1 (0.68) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL28215372 | 0.96 | ALDH1A1 (0.65) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL10585434 | 0.91 | ALDH1A1 (0.71) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL27261063 | 0.90 | ALDH1A1 (0.58) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL28380726 | 0.87 | ALDH1A1 (0.65) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL27899272 | 0.86 | — | — | |
| Aminothiazole SCHEMBL5907076 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL28006118 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL1241596 | 0.84 | ALDH1A1 (0.75) | ALDH1A1TSHRNOS1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060149056-A1 | Stable bioavailable crystalline form of cefdinir and a process for the preparation thereof | LUPIN LTD (IN) | 2006-07-06 | — | — | US | disclosed |
| US-20050245738-A1 | Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof | LUPIN LTD (IN) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245738-A1 | Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof | DCXR, CYP4F8, CYP2F1 | NOS1 2602/4885ALDH1A1 3253/4885TSHR 3264/4885 |
| US-20060149056-A1 | Stable bioavailable crystalline form of cefdinir and a process for the preparation thereof | DCXR, CYP4F8, ABCG2 | NOS1 2601/4885ALDH1A1 3143/4885TSHR 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.